BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 29311707)

  • 1. Associations of Tumor PD-1 Ligands, Immunohistochemical Studies, and Textural Features in
    Chen RY; Lin YC; Shen WC; Hsieh TC; Yen KY; Chen SW; Kao CH
    Sci Rep; 2018 Jan; 8(1):105. PubMed ID: 29311707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on
    Takada K; Toyokawa G; Okamoto T; Baba S; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Honda H; Oda Y; Maehara Y
    Cancer Med; 2017 Nov; 6(11):2552-2561. PubMed ID: 28980429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma.
    Kasahara N; Kaira K; Bao P; Higuchi T; Arisaka Y; Erkhem-Ochir B; Sunaga N; Ohtaki Y; Yajima T; Kosaka T; Oyama T; Yokobori T; Asao T; Nishiyama M; Tsushima Y; Kuwano H; Shimizu K; Mogi A
    Lung Cancer; 2018 May; 119():71-77. PubMed ID: 29656756
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Verhoeff SR; van de Donk PP; Aarntzen EHJG; Oosting SF; Brouwers AH; Miedema IHC; Voortman J; Menke-van der Houven van Oordt WC; Boellaard R; Vriens D; Slingerland M; Hermsen R; Grunsven IVE; Heskamp S; van Herpen CML
    J Nucl Med; 2022 Oct; 63(10):1523-1530. PubMed ID: 35512998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic value of
    Togo M; Yokobori T; Shimizu K; Handa T; Kaira K; Sano T; Tsukagoshi M; Higuchi T; Yokoo S; Shirabe K; Oyama T
    Br J Cancer; 2020 May; 122(11):1686-1694. PubMed ID: 32238919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma.
    Schoenfeld JD; Gjini E; Rodig SJ; Tishler RB; Rawal B; Catalano PJ; Uppaluri R; Haddad RI; Hanna GJ; Chau NG; Rabinowits G; Lorch J; Jo VY; Krane JF; Goguen LA; Annino DJ; Abdelrahman S; Lipschitz M; Margalit DN
    Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):137-145. PubMed ID: 29960819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
    Balermpas P; Rödel F; Krause M; Linge A; Lohaus F; Baumann M; Tinhofer I; Budach V; Sak A; Stuschke M; Gkika E; Grosu AL; Abdollahi A; Debus J; Stangl S; Ganswindt U; Belka C; Pigorsch S; Multhoff G; Combs SE; Welz S; Zips D; Lim SY; Rödel C; Fokas E;
    Int J Cancer; 2017 Aug; 141(3):594-603. PubMed ID: 28480996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical biomarkers and FDG uptake on PET/CT in head and neck squamous cell carcinoma.
    Rasmussen GB; Vogelius IR; Rasmussen JH; Schumaker L; Ioffe O; Cullen K; Fischer BM; Therkildsen MH; Specht L; Bentzen SM
    Acta Oncol; 2015; 54(9):1408-15. PubMed ID: 26256482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between PD-L1 Expression and Metabolic Activity on
    Takada K; Toyokawa G; Tagawa T; Kohashi K; Akamine T; Takamori S; Hirai F; Shoji F; Okamoto T; Oda Y; Maehara Y
    Anticancer Res; 2017 Dec; 37(12):7073-7082. PubMed ID: 29187498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation.
    Rühle A; Grosu AL; Wiedenmann N; Mix M; Stoian R; Niedermann G; Baltas D; Werner M; Weber WA; Kayser G; Nicolay NH
    Theranostics; 2020; 10(20):9395-9406. PubMed ID: 32802199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia, blood flow and metabolism in squamous-cell carcinoma of the head and neck: correlations between multiple immunohistochemical parameters and PET.
    Grönroos TJ; Lehtiö K; Söderström KO; Kronqvist P; Laine J; Eskola O; Viljanen T; Grénman R; Solin O; Minn H
    BMC Cancer; 2014 Nov; 14():876. PubMed ID: 25421331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma.
    Roper E; Lum T; Palme CE; Ashford B; Ch'ng S; Ranson M; Boyer M; Clark J; Gupta R
    Pathology; 2017 Aug; 49(5):499-505. PubMed ID: 28666643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck.
    De Meulenaere A; Vermassen T; Aspeslagh S; Huvenne W; Van Dorpe J; Ferdinande L; Rottey S
    Oral Oncol; 2017 Jul; 70():34-42. PubMed ID: 28622889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
    Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
    Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for PD-L1 expression in non-small cell lung cancer: A systematic review and meta-analysis.
    Seol HY; Kim YS; Kim SJ
    Thorac Cancer; 2020 Nov; 11(11):3260-3268. PubMed ID: 32951338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Construction of A Nomogram Prediction Model for PD-L1 Expression 
in Non-small Cell Lung Cancer Based on 18F-FDG PET/CT Metabolic Parameters].
    Hao L; Wang L; Zhang M; Yan J; Zhang F
    Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):833-842. PubMed ID: 38061885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications.
    Wolkow N; Jakobiec FA; Afrogheh AH; Eagle RC; Pai SI; Faquin WC
    Am J Ophthalmol; 2019 Apr; 200():226-241. PubMed ID: 30633894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic performance of
    Chaput A; Robin P; Podeur F; Ollivier M; Keromnes N; Tissot V; Nonent M; Salaün PY; Rousset J; Abgral R
    Laryngoscope; 2018 Feb; 128(2):378-385. PubMed ID: 28600822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and Biological Significance of PD-L1 Expression Within the Tumor Microenvironment of Oral Squamous Cell Carcinoma.
    Takahashi H; Sakakura K; Arisaka Y; Tokue A; Kaira K; Tada H; Higuchi T; Okamoto A; Tsushima Y; Chikamatsu K
    Anticancer Res; 2019 Jun; 39(6):3039-3046. PubMed ID: 31177146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.